Suven Life Sciences has commenced Phase I clinical trial of its new chemical entity (NCE) for the treatment of cognitive dysfunction associated with Alzheimer’s disease and Schizophrenia in the US. The NCE has completed all the pre-clinical, safety and toxicological studies and was submitted for Investigational New Drug Application to conduct Phase I clinical trial with the indication for cognition in Alzheimer’s disease under the Federal Food, Drug and Cosmetic Act, a company release stated.
“The second compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer’s and Schizophrenia with high unmet medical need, which has huge market potential globally,” said Venkat Jasti, CEO, Suven.
Suven has 11 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as attention deficit hyperactive disorder, dementia, major depressive disorder, Huntington’s disease, Parkinson's disease and obesity in addition to this phase I developmental candidate and a phase II developmental candidate for Alzheimer’s disease and Schizophrenia.
“The second compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer’s and Schizophrenia with high unmet medical need, which has huge market potential globally,” said Venkat Jasti, CEO, Suven.
Suven has 11 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as attention deficit hyperactive disorder, dementia, major depressive disorder, Huntington’s disease, Parkinson's disease and obesity in addition to this phase I developmental candidate and a phase II developmental candidate for Alzheimer’s disease and Schizophrenia.